OCGN Latest Press Releases

-- October 22, 2026 --

Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4 Globe Newswire 7:00 AM

-- October 14, 2026 --

Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa Globe Newswire 6:30 AM

-- October 8, 2026 --

Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PRNewswire 2:51 PM

-- October 6, 2026 --

Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate Globe Newswire 7:02 AM

-- September 30, 2026 --

Ocugen to Participate in Upcoming Scientific Conferences Globe Newswire 7:02 AM

-- September 29, 2026 --

Ocugen to Participate in Upcoming October Investor and Industry Conferences Globe Newswire 7:02 AM

-- September 25, 2026 --

Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa Globe Newswire 7:02 AM

-- September 1, 2026 --

Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Globe Newswire 7:02 AM

-- August 25, 2026 --

Ocugen to Participate in Upcoming September Investor and Industry Conferences Globe Newswire 7:02 AM

-- August 6, 2026 --

Ocugen Provides Business Update with Second Quarter 2026 Financial Results Globe Newswire 7:02 AM

-- July 31, 2026 --

Ocugen to Participate in Upcoming August Investor Conferences Globe Newswire 7:02 AM

-- July 29, 2026 --

Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration Globe Newswire 7:01 AM

-- July 28, 2026 --

Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results Globe Newswire 4:01 PM

-- July 13, 2026 --

Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa Globe Newswire 7:02 AM

-- July 1, 2026 --

Ocugen to Participate in Upcoming July Industry Conferences Globe Newswire 7:00 AM

-- June 2, 2026 --

Ocugen to Participate in Upcoming June Investor and Industry Conferences Globe Newswire 7:03 AM

Market Data Delayed 15 Minutes